Keros Therapeutics

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

At Keros we strive to bring meaningful therapeutic advances to patients and their families, through innovative proficiency and dedication to discovering and developing novel and safe drugs with disease-modifying capability.

Our vision is to create innovative clinical solutions that will profoundly improve and potentially save the lives of individuals with serious and rare diseases.

Keros has received more than 20 industry awards, including the MassBioEd 2018 Innovation Award and the 2017 BioInnovations Catalyst Award from MassBesTech, as well as the 2017 Rising Star Award and the 2018 Safety and Innovation Award from BioPharma Asia.